Our previous study demonstrated that CpG oligodeoxynucleotides (CpG ODNs), which were under investigation as adjuvant in therapy against infections and cancers, could effectively activate the TLR9 signaling pathway in human lung cancer cells and thus promoted the tumor progression both in vitro and in vivo [3], [4], [9]–[11]. This evidence concerns the gene TLR9 and lung cancer.